Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
AprilBio Co.,Ltd. Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.	South Korea	397030
Aprogen Biologics Inc. Develops and manufactures novel biologic drugs and biosimilars for the professional market.	South Korea	003060
Aprogen, Inc Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.	South Korea	007460
Aptabio Therapeutics Inc. Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.	South Korea	293780
Aptahem AB Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.	Sweden	APTA
Aptamer Sciences Inc Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.	South Korea	291650
Aptevo Therapeutics Inc. Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.	United States of America	APVO
Aptorum Group Ltd Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.	United States of America	APM
Aquestive Therapeutics, Inc. Develops oral film drugs for CNS disorders and severe allergies.	United States of America	AQST
Arbutus Biopharma Corp A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).	United States of America	ABUS